2024 was a great year for the economy in Rapid City
Thanks to local attractions and kids sports, more people are spending time in South Dakota's second largest city.
Last year Rapid City welcomed 100,000 more visitors. Spending was also up $25 Million from 2023.
'So one of the neat things about the Black Hills is that it is multi-generational. So grandpa and grandma came as kids, then they brought their kids, now they're bringing their grandkids and the Black Hills has always been that. The other neat thing and this really does kind of isolate us from what's going on in the National Economy is that we are a pretty significant drive market .' Visit Rapid City President Brook Kaufman Said
This continued growth in tourism has been helped by the growth of youth sporting events in the area.
'It's all just part of the puzzle of overall tourism. Sports is a big contributor, but so are meetings and conventions. Sports we do really well because it's the time of year when we don't have traditional tourism.' Executive Director Domico Rodriguez
Over the past month, Rapid City hosted 3 successful state tournaments.
'There's a youth tournament almost every weekend in the area of some sport in the winter. And trying to capitalize on that and grow those events, will only help the bottom line for all of our attractions, hotels and restaurants.' Rodriguez Said
'Our sporting tournaments last year and we're going to see that again in 25, we have a very robust leisure visitor. We kind of transition, we see families in the summer and then we transition to older couples that are here that are maybe retired and they have a little bit more time. What I can tell you is that constantly what we hear is I wish I would've stayed longer.' Kaufman Said
These numbers also show that the tourism economy generated over $113 Million in government revenue, saving each household close to $2,000 in taxes.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Fluent: Q2 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Fluent, Inc. (FLNT) on Tuesday reported a loss of $7.2 million in its second quarter. The New York-based company said it had a loss of 30 cents per share. Losses, adjusted for one-time gains and costs, were 24 cents per share. The data and analytics company posted revenue of $44.7 million in the period. _____
Miami Herald
an hour ago
- Miami Herald
Unusual Machines Secures $1.6 Million Order for Aura Cameras and HDO+ Goggles to Support U.S. Defense Supply Chain
ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a provider of NDAA-compliant drone components, today announced a $1.6 million purchase of Fat Shark Aura cameras and HDO+ goggles placed by a domestic defense drone manufacturer. The components will be delivered through the U.S. defense supply chain, reinforcing Unusual Machines' role as a trusted supplier of compliant equipment. The Fat Shark Aura cameras are included in the Blue UAS Framework, confirming compliance with Department of Defense and NDAA standards. The HDO+ goggles offer high-clarity optics with the largest field of view of any analog FPV headset currently on the market, allowing operators to switch between 4:3 and 16:9 aspect ratios without narrowing the field of vision. Production will begin immediately, with initial deliveries scheduled for the end of September and the remainder completed by December. "This order represents a milestone for Unusual Machines and, importantly, reflects the trust our customers place in us to deliver large quantities of critical components," said Allan Evans, CEO of Unusual Machines. "By keeping cash reserves strong, scaling inventory ahead of demand, and strengthening our supply chain for larger volumes, we can execute quickly and reliably. This mindset allows us to accelerate delivery, ensure dependability, and expand manufacturing so more drone capability is built in the United States." Today's announcement reflects the growing scale of opportunities for Unusual Machines. While this order will ship from existing production lines, the upcoming U.S.-based manufacturing facility for HDO+ goggles underscores the company's long-term strategy to onshore even more production, keep pace with government demand, and deliver the capacity needed for future growth. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements include: our expectation that we will deliver initial orders of the Aura cameras and HDO+ goggles by the end of September 2025 and the balance of the orders by December 2025, our ability to execute orders, our quickly and reliably, and our expectation that we will be successful leasing a new facility and expand our manufacturing footprint and build our headset production capabilities. The results expected by some or all of these forward-looking statements may not occur. Factors that affect our ability to achieve these results include our expectation that we will commence operations in our new Orlando manufacturing facility in September 2025 and close the Rotor Lab acquisition in the third quarter of 2025, the continued availability of commercial real estate near our Orlando, Florida facilities, the availability of a satisfactory labor pool, potential supply chain issues, the impact from tariffs including inflation, and the Risk Factors contained in our Form 10-Q, filed with the SEC on May 8, 2025, Prospectus Supplement filed with the Securities and Exchange Commission (the "SEC") on March 6, 2025 and in our Form 10-K for the year ended December 31, 2024. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Any forward-looking statement made by us herein speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. About Unusual Machines Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit Investor Contact: CS Investor Relationsinvestors@ Media Contact: media@ SOURCE: Unusual Machines, Inc.
Business Wire
an hour ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
